Vascular News

23/02/2026

Humacyte recently announced the presentation of 36-month data assessing the durability of its Symvess acellular tissue-engineered vessel in extremity arterial trauma patients.

Humacyte recently announced the presentation of 36-month data assessing the durability of Symvess in extremity arterial trauma patients.

20/02/2026

Ben Li (Toronto, Canada) ponders the current state of artificial intelligence (AI) application in clinical practice, analysing the obstacles to scaled use.

Ben Li (Toronto, Canada) ponders the current state of AI application in clinical practice, analysing the obstacles to scaled use.

19/02/2026

Preliminary three-month results from the first five human implantations of StentIt’s resorbable fibrillated scaffold (RFS) reveal a technical success rate of 100% and no device- or procedure-related serious adverse events at 30 days in patients with below-the-knee (BTK) chronic limb-threatening ischaemia (CLTI).

Marianne Brodmann (Graz, Austria) shared early findings from the VITAL-IT 1 study as a first-time data release at LINC 2026.

16/02/2026

INTERVIEW: Despite original ambitions to become a journalist, the loss of a close relative to pulmonary embolism (PE) saw Marianne Brodmann (Graz, Austria) redirect her focus towards the medical world. Now the head of the Division of Angiology at the Medical University of Graz, Brodmann talks bioresorbable scaffold technologies, CREST-2, and artificial intelligence ( ) in this interview with Vascular News on her life and career in the vascular field thus far.

Marianne Brodmann talks bioresorbable scaffold technologies, CREST-2, and AI in an interview on her life and career in the vascular field thus far.

12/11/2024

You have a long complex SFA lesion, what do you do?​

DCB+/-bailout stent or go direct with Eluvia DES?​

Find out what the experts Prof. Giovanni Torsello and Prof. Gunnar Tepe think: https://vascularnews.com/real-world-registry-shows-sustained-efficacy-for-eluvia-des-in-the-sfa/

Want to know more about Eluvia? https://www.bostonscientific.com/en-EU/medical-specialties/vascular-surgery/drug-eluting-stent-drug-coated-balloon.html



Sponsored by Boston Scientific

02/07/2024

FORS-powered LumiGuide has “gold-standard” potential for 3D device guidance without radiation

A new technology is set to change the endovascular game by offering 3D, full-colour guidance to replace the 2D, greyscale standard-of-care. The result? Increased visualisation without the use of fluoroscopy. This is one of the key messages to have emerged from a roundtable discussion at the recent Charing Cross (CX) International Symposium (23–25 April, London, UK) on complex aortic procedures, Fiber Optic RealShape (FORS) technology, and the latest from Philips—FORS-powered LumiGuide.

The CX discussion saw aortic experts Bijan Modarai (London, UK), Isabelle van Herzeele (Ghent, Belgium) and Laurent Chiche (Paris, France) all share their experience with and expert opinions on Philips’ imaging offering for complex aortic procedures.

The speakers highlighted the issue of increased radiation exposure that is associated with the increased complexity of endovascular cases. The solution that they suggest is the FORS-powered LumiGuide (Philips), which provides 3D device guidance using light that aims to offer better visualisation in full colour, with minimal need for fluoroscopy.



This post is by Philips.

www.philips.com/LumiGuide

Bijan Modarai Isabelle Van Herzeele Laurent Chiche Philips Imaging Atul Gupta, MD

11/06/2024

Vicente Riambau (Barcelona, Spain) describes the unique features and improvements of the iCover balloon expandable covered stent, notably its low profile, radiopaque markers, and total encapsulation with polytetrafluoroethylene (ePTFE), which give the device an edge over its competitors and make it his “first choice.”

Riambau also reflects on how iVascular’s vertical integration, by which the company manufactures all product components such as plastic tubes, balloons and stents, allows freedom from supply chain difficulties. This is important, he says, to maintain high quality for every single step during the manufacture of key parts.

https://vascularnews.com/icovers-radiopaque-markers-and-full-encapsulation-with-small-profiles-help-it-stand-out-from-competitors/

This video is sponsored by
iVascular

04/06/2024

Andrew Holden (Auckland, New Zealand), one of the co-chairs of the Charing Cross (CX) International Symposium, presented the final five-year data on the vital status of patients enrolled in the IN.PACT AV Access pivotal trial in April 2024 as a podium-first presentation. Due to the paclitaxel safety concerns raised, the researchers re-consented patients enrolled in the trial to prolong the follow-up period to establish their long-term vital status.

“The all-cause mortality remains the same out to five years. There is no mortality concern using the IN.PACT [AV] drug-coated balloon (DCB). The long-term durability of this study really shows that the IN.PACT DCB should be the standard of care in maintaining [the] AV [arteriovenous] access circuit,” Holden said, reminding the audience that this is the only randomised, pivotal trial in AV access circuits to demonstrate a consistent and sustained clinical benefit out to three years.

The IN.PACT AV Access randomised controlled trial comparing plain balloon angioplasty with DCB angioplasty in managing stenotic disease in AV access has previously shown significantly improved sustained benefits for end-stage kidney disease patients at the three-year time point. Further research has also demonstrated a cost-effectiveness advantage for healthcare systems in Japan, Korea and the USA, when the device is used.

Watch now: https://vascularnews.com/first-time-presentation-of-in-pact-av-access-five-year-data-lays-paclitaxel-mortality-concerns-to-rest/

This video is sponsored by Medtronic.

27/05/2024

Are you an early bird?🐤

Attend the Annual Meeting in Kraków at a discounted price.

Anticipate controversial debates, our best-selling workshops, and of course, a lot of fun!💃

Hurry, the discount is only available until the 9th of July!

🎟️https://esvs.org/events/annual-meeting/annual-meeting-2024/registration-accomodation/

22/04/2024

We look forward to meeting you at the , from Apr 23-25 in London. Stop by the Teleflex booth n. 107 and join us for our Hands-on training sessions with the advanced pulsatile MANTA simulator and learn how to close arteriotomies as large as 25F OD using MANTA Vascular Closure Device!



https://irc.teleflex.com/manta-emea/

Sponsored by Teleflex

15/04/2024

GREAT BENEFITS THROUGH THE INTERACTION OF ZIEHM VISION RFD HYBRID EDITION AND THERENVA

With its zero room preparation, the comprehensive mobile hybrid solution easily takes your OR to the next level. Plug in your system and start your hybrid procedure.

Visit us at booth #209 and experience the workstation for testing Therenva EndoSize on site.

Take part in our two exciting live workshops:

- “Intraoperative 3D vascular navigation using a complete mobile hybrid solution” - Tuesday, April 23rd

- “From pre-operative sizing to OR with assisted 3D guidance to enhance endovascular procedures - Powered by EndoSize and EndoNaut” - Thursday, April 25th



Sponsored by Ziehm Imaging

09/04/2024

This year marks a significant milestone as BD celebrates 25 years of its Rotarex™S rotational atherothrombectomy system, a journey that started in the Swiss mountains with Immanuel Straub, and has today touched the lives of over 250,000 patients. In this article, Vascular News outlines the heritage and history of the device and presents a case report from Mark Portou (Royal Free Hospital, London, UK) highlighting its continued real-world application and outcomes.

The story of RotarexS begins in the early 1990s, when Immanuel Straub, a Swiss engineer and founder of Straub Medical, teamed up with a medical doctor to create a tool to treat . Straub combined knowledge from Swiss watchmakers (specialists in micro engineering) and Swiss mountain tunnellers (with their ability to break through the toughest materials) and along with his own expertise in creating high-quality and high-durability springs for the car industry, they came up with a concept for the treatment of arterial blockages. This concept became RotarexS.

Read more: https://vascularnews.com/rotarexs-a-25-year-legacy-continues/

Advertorial sponsored by Beckton Dickinson

This year marks a significant milestone as BD celebrates 25 years of its RotarexS rotational atherothrombectomy system.